Most of these effects are based on changes in the internal environment and drug interactions caused by radiotherapy, such as adjuvant enhancement of capecitabine or anthracyclines in triple-negative breast cancer (TNBC) and CDK4/6 inhibitors in luminal subtype patients with a high risk of recurrence after surgery. Here, CDK4 is linked to triple-negative breast carcinoma.